

Financial Tear Sheet




Corporate Profile

Who is Organovo?

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong IP portfolio
- We're leveraging our technology platform to build a robust product and service platform across the preclinical safety, efficacy and disease modeling and therapeutic tissues markets

Primary IR Contact

Steve E. Kunszabo
 VP, Investor Relations &
 Corporate
 Communications
Phone: 858-224-1092
Email:
 skunszabo@organovo.com

 2017 Annual Report
  Investor Fact Sheet
  Investor Presentation

Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.01
Change (%)	▼ 0.07 (3.37%)
Volume	607,397
52 Week Low	\$2.00
Market Cap	\$220,735,940
Rolling EPS	-0.39
PE Ratio	0
Shares Outstanding	106,123,048
Data as of 08/17/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

08/09/17

Organovo Announces Fiscal First-Quarter 2018 Results; Company Affirms Full-Year Fiscal 2018 Outlook

07/31/17

Organovo and UC San Diego Receive \$1.7 Million Grant From National Institutes of Health to Study Liver Disease

07/18/17

Organovo Announces Release Date for Fiscal First-Quarter 2018 Financial Results

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/17/17	4
08/17/17	4
08/17/17	4
08/17/17	4

Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Vice President, Human Resources
Paul Gallant	General Manager